1 / 1

Sofosbuvir/Velpatasvir/Voxilaprevir(Vosevi)

Acetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine InjectionAcetylcysteine Injection, FLUIMUCIL, Acetylcysteine Injection

Reference price:

Manufacturer:

Gilead

Formulation:

TABLET

Validity period:

24 months

Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.

Vosevi(Sofosbuvir/Velpatasvir/Voxilaprevir) Instructions:Uses,Dosage, Side Effects

VOSEVI is a fixed-dose combination tablet containing three direct-acting antiviral agents: sofosbuvir, velpatasvir, and voxilaprevir. It is designed as a salvage therapy for adult patients with chronic hepatitis C virus (HCV) infection, targeting multiple viral proteins to inhibit replication.

The tablet is formulated for oral administration and is specifically indicated for patients who have prior treatment experience with certain HCV regimens, particularly those involving NS5A inhibitors or sofosbuvir without an NS5A inhibitor.

Generic name

Sofosbuvir/Velpatasvir/Voxilaprevir(Vosevi)

English name

Sofosbuvir/Velpatasvir/Voxilaprevir

Alternative Names

Vosevi

Drug prices

Indications

Genotype 1, 2, 3, 4, 5, or 6 infection in patients previously treated with an HCV regimen containing an NS5A inhibitor.

Genotype 1a or 3 infection in patients previously treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor.

Therapeutic Target

Hepatitis C virus (HCV) NS5B polymerase, NS5A protein, and NS3/4A protease

Active Ingredients

Sofosbuvir 400 mg, Velpatasvir 100 mg, Voxilaprevir 100 mg

Dosage form

TABLET

specifications

400mg/100mg/100mg*28 tables /bottle

Description

Dosage and Administration

One tablet taken orally once daily with food.

Treatment duration is 12 weeks.

CATEGORY NAVIGATION